Prostate cancer
Conditions
Interventions
None listed
Sponsors
Tohoku University, Dept. of urology
Hirosaki University, Dept. of urology Akita University, Dept. of urology Ryukyu University, Dept. of urology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Clinically T1-4 patient of prostate cancer(anyN, anyM) 2) No previous hormonal treatment. 3) Performance status 0-1 (ECOG) 4) Patients who satisfy the following a) WBC>3.0x103/uL b) hemoglobin>10.0 g/dL c) platelet>10x104/uL d) serum creatinine<2.0 mg/dL e) AST100<IU/L f) ALT100<IU/L 5) Patients who will receive hormonal therapy more than 1 year 6) 20<Age<85 years/old 7) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients who have active another cancer 2) serious cardiovascular disease 3) uncontrollable diabetes 4) patients with hyperthyroidism, cushing syndrome, nephrotic syndrome 5) treated with estrogen (eg. Ethinylestradiol, estramustine) 6) treated with antiandrogen (eg. prostal) for benign prostatic hyperplasia 7) treated with 5alpha-reductase inhibitor (eg. dutasteride) for benign prostatic hyperplasia 8) treated with steroids (exclude external use for skin) 9) treated with other anticancer drugs 10) Patient who enrolled other clinical studies. 11) Patients who considered inappropriate for this trial by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change in serum lipid (total cholesterol, triglyceride, HDL and LDL-cholesterol) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Percent change in fasting serum glucose. 2. Changes in body weight, waist circumference and body mass index (BMI). 3. Changes in abdominal fat area 4. Adverse events | — |
Countries
Japan
Contacts
Public ContactKoji Mitsuzuka
Tohoku University, Dept. of urology Urology
Outcome results
None listed